Rivastigmine: all 62 studies that test it

Page 1 of 1. Open to participants first (1), then studies with results posted, then the rest; newest registration first within each.

• Rivastigmine for Antimuscarinic DeliriumRecruitingNCT06382649Phase 2
• Effect of Heat on Rivastigmine TDS ProductsCompletedNCT03915626Early Phase 1Results posted
• A Phase IV Study to Evaluate Safety, Tolerability and Effectiveness of Rivastigmine Patch 15cm2 in Patients With Severe Dementia of the Alzheimer's Type.CompletedNCT02989402Phase 4Results posted
• NextStep:Study to Evaluate Safety,Efficacy & Tolerability of Rivastigmine Patch in Mild to Moderate Alzheimer's Patients.CompletedNCT02703636Phase 4Results posted
• 16w Interventional Study on Titration and Dose/Efficacy Assessment of Exelon in Chinese Alzheimer's Disease PatientsCompletedNCT01948791Phase 4Results posted
• Rivastigmine Patch in Veterans With Cognitive Impairment Following TBICompletedNCT01670526Phase 3Results posted
• Study of Exelon Transdermal Patch in Amnestic Mild Cognitive Impairment PatientsTerminatedNCT01602198Not applicableResults posted
• Tolerability of Rivastigmine Before and After Switching From Oral Formulation to Transdermal Patch in Alzheimer's DementiaCompletedNCT01585272Phase 4Results posted
• Mild Cognitive Impairment in Parkinson's DiseaseCompletedNCT01519271Phase 4Results posted
• A 24-Week Efficacy, Safety and Tolerability of Rivastigmine Patch Study in Patients With Probable Alzheimer's DiseaseCompletedNCT01399125Phase 3Results posted
• Comparative Research of Alzheimer's Disease DrugsTerminatedNCT01362686Not applicableResults posted
• Cognitive Decline in Non-demented PDCompletedNCT01340885Phase 4Results posted
• Rivastigmine Study in Adolescents With Down SyndromeCompletedNCT01084135Phase 1/2Results posted
• Effects of Rivastigmine Patch on Activities of Daily Living and Cognition in Patients With Severe Dementia of the Alzheimer's Type (ACTION) (Study Protocol CENA713DUS44, NCT00948766) and a 24 Week Open-label Extension to Study CENA713DUS44CompletedNCT00948766Phase 4Results posted
• Rivastigmine in Multiple Sclerosis Patients With Cognitive ImpairmentTerminatedNCT00881205Phase 4Results posted
• Rivastigmine in the Treatment of Postoperative Delirium: a Pilot Clinical TrialCompletedNCT00835159Phase 4Results posted
• Long-term Safety of Rivastigmine Capsule and Patch in Patients With Mild to Moderately-severe Dementia Associated With Parkinson's Disease (PDD)CompletedNCT00623103Phase 3Results posted
• A 24 Week, Multicenter, Open, Evaluation of the Clinical Effectiveness of the Once-daily 10 cm^2 Rivastigmine Patch Formulation in Patients With Probable Alzheimer's Disease (EXTRA)CompletedNCT00622713Phase 4Results posted
• Convenience, Tolerability, and Safety of Change in the Administration of Rivastigmine From Capsules to a Transdermal Patch in Patients With Mild to Moderate Alzheimer's DiseaseCompletedNCT00549601Phase 4Results posted
• Comparative Efficacy, Safety, and Tolerability of Rivastigmine 10 and 15 cm^2 Patch in Patients With Alzheimer's Disease (AD) Showing Cognitive DeclineCompletedNCT00506415Phase 3Results posted
• Efficacy and Safety of Rivastigmine Transdermal Patch in Patients With Mild to Moderate Alzheimer's DiseaseCompletedNCT00423085Phase 3Results posted
• Rivastigmine as an Antidote for Clozapine-induced Central Nervous System Depression and DeliriumCompletedNCT07545382Phase 4
• Rivastigmine to Prevent Recurrence of Antimuscarinic DeliriumSuspendedNCT06399679Phase 2
• Rivastigmine Patch Compared to Melatonin Patch in Prevention of Postoperative DeliriumCompletedNCT04189666Phase 1/2
• Noradrenaline, Acetylcholine and Dynamic Learning in Healthy HumansCompletedNCT03957174Not applicable
• Cholinergic Neurotransmission in Mobility and Cognition in Parkinson DiseaseCompletedNCT03840837Phase 4
• Efficacy of RIVAstigmine on Motor, Cognitive and Behavioural Impairment in Progressive Supranuclear PalsyCompletedNCT02839642Phase 3
• Open Label Trial of Rivastigmine Patch in Subjects With Mild to Moderate Stage AD Having Coexisting svCVDCompletedNCT02444637Phase 4
• Rivastigmine Patch Effect on the Post-operative Delirium in Patients at Risk of Dementia.CompletedNCT02413554Phase 4
• Pharmacovigilance in Gerontopsychiatric PatientsTerminatedNCT02374567Phase 3
• Brain Changes by Rivastigmine According to Butyrylcholinesterase AllelesStatus unknownNCT02063269Not applicable
• Cholinesterase Inhibitors to Slow Progression of Visual Hallucinations in Parkinson&Apos;s DiseaseTerminatedNCT01856738Phase 4
• Efficacy, Safety and Tolerability of Rivastigmine Patch in Patients With Mild to Moderate Alzheimer's Disease Switched From Cholinesterase InhibitorsCompletedNCT01529619Phase 4
• Rivastigmine in the Management of DeliriumCompletedNCT01487317Phase 3
• Cognitive Changes in Alzheimer's Disease Patients Associated With or Without White Matter Changes After RivastigmineCompletedNCT01380288Not applicable
• Bioequivalence Study of Rivastigmine 1.5 mg Capsules Under Fasting ConditionsCompletedNCT01146067Phase 1
• Bioequivalence Study of Rivastigmine Capsules 1.5 mg of Dr.Reddy's Under Fed ConditionsCompletedNCT01146041Phase 1
• Rivastigmine as a Treatment for Methamphetamine DependenceCompletedNCT01073319Phase 1
• Rivastigmine and Huperzine A as Treatments for Cocaine DependenceCompletedNCT01030692Phase 1
• Exelon Patch and Combination With Memantine Comparative TrialCompletedNCT01025466Phase 4
• Study of Rivastigmine to Treat Parkinsonian Apathy Without DementiaCompletedNCT00767091Phase 3
• Efficacy of Rivastigmine in Patients With Down SyndromeCompletedNCT00748007Not applicable
• Compliance and Tolerability of Rivastigmine Transdermal Patch 10 cm² in Patients With Probable Alzheimer's Disease.CompletedNCT00731224Phase 4
• Rivastigmine for Intensive Care Unit (ICU) DeliriumTerminatedNCT00704301Phase 4
• RIVastigmine In Vascular cognitivE ImpairmentCompletedNCT00669344Phase 4
• Rivastigmine in Mild Alzheimer's Disease, FMRI StudyCompletedNCT00627848Not applicable
• A Double-Blind, Placebo-controlled Crossover Study of Repeat Rivastigmine Administration in Healthy Male VolunteersCompletedNCT00624663Not applicable
• Methylphenidate, Rivastigmine or Haloperidol in Hypoactive Delirium in Intensive Care PatientsTerminatedNCT00599287Phase 3
• Efficacy Study for Treatment of Dementia in Progressive Supranuclear PalsyStatus unknownNCT00522015Phase 2
• Safety and Tolerability of Rivastigmine With Add-on Memantine in Patients With Probable Alzheimer's DiseaseCompletedNCT00305903Phase 4
• Rivastigmine Monotherapy and Combination Therapy With Memantine in Patients With Moderately Severe Alzheimer's Disease Who Failed to Benefit From Previous Cholinesterase Inhibitor TreatmentCompletedNCT00234637Phase 4
• Treatment of Orthostatic Hypotension in Autonomic FailureCompletedNCT00223691Phase 1
• An Extension Study Evaluating the Efficacy and Safety of Rivastigmine in Patients With Traumatic Brain Injury (TBI) With Persistent Cognitive DeficitsCompletedNCT00219245Phase 4
• An Open-label Extension to Evaluate the Efficacy and Safety of the Rivastigmine Transdermal Patch in Patients With Probable Alzheimer's DiseaseCompletedNCT00219232Phase 3
• Efficacy and Safety of Rivastigmine in Patients With Traumatic Brain Injury and Cognitive ImpairmentCompletedNCT00171795Phase 3
• Rivastigmine For Methamphetamine Dependent IndividualsCompletedNCT00158210Phase 1
• Efficacy and Safety of Rivastigmine in Patients With Mild Cognitive ImpairmentTerminatedNCT00134953Phase 3
• Rivastigmine Capsules in Patients With Probable Vascular DementiaCompletedNCT00130338Phase 3
• Study of the Effects of Current Drug Treatments on Levels of Certain Brain Chemicals in Alzheimer's DiseaseCompletedNCT00104442Phase 4
• Efficacy and Safety of the Rivastigmine Transdermal Patch in Patients With Probable Alzheimer's DiseaseCompletedNCT00099242Phase 3
• Efficacy and Safety of Rivastigmine Capsules in Patients With Probable Vascular DementiaCompletedNCT00099216Phase 3
• Investigation Into Delay to Diagnosis of Alzheimer's Disease With Exelon (InDDEx)CompletedNCT00000174Phase 3

← Rivastigmine overview